---

$0.40

+0.0172 ( +4.51% ) 0.5K

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-12-16	Buy	20000.00	MARIANI PETER J
2024-12-13	Buy	11363.00	MARIANI PETER J
2024-04-04	Sale	-44000.00	BATOR MICHAEL G.
2024-04-04	Sale	-22000.00	Kim Jiny
2024-04-04	Sale	-96000.00	Chan Phillip P.
2024-04-04	Sale	-61000.00	Deliargyris Efthymios
2024-04-04	Sale	-22000.00	Sobel Alan D.
2024-04-04	Sale	-81000.00	Capponi Vincent
2024-04-04	Sale	-22000.00	Jones Edward Raymond
2024-04-04	Sale	-65000.00	BLOCH KATHLEEN P.